Last reviewed · How we verify
Enalapril/folic acid
Enalapril inhibits angiotensin-converting enzyme (ACE) to reduce blood pressure, while folic acid supplementation supports cardiovascular health and may reduce homocysteine levels.
Enalapril inhibits angiotensin-converting enzyme (ACE) to reduce blood pressure, while folic acid supplementation supports cardiovascular health and may reduce homocysteine levels. Used for Hypertension, Heart failure, Post-myocardial infarction.
At a glance
| Generic name | Enalapril/folic acid |
|---|---|
| Also known as | Enalapril Maleate and Folic Acid Tablet |
| Sponsor | Shenzhen Ausa Pharmed Co.,Ltd |
| Drug class | ACE inhibitor with vitamin supplement |
| Target | Angiotensin-converting enzyme (ACE) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Enalapril is an ACE inhibitor that blocks the conversion of angiotensin I to angiotensin II, leading to vasodilation and reduced blood pressure. Folic acid is included as a B-vitamin supplement to support overall cardiovascular health and potentially mitigate homocysteine elevation, which can be a risk factor in hypertension management. This combination addresses both the primary antihypertensive effect and nutritional support.
Approved indications
- Hypertension
- Heart failure
- Post-myocardial infarction
Common side effects
- Cough
- Dizziness
- Fatigue
- Hyperkalemia
- Angioedema
Key clinical trials
- Enalapril Folic Acid Tablets Combined With CCB or Diuretic to Prevent Stroke in Patients With Type H Hypertension (PHASE3)
- A Pharmacogenomics Study of Safety and Efficacy of Enalapril or Enalapril-Folic Acid Therapy in Hypertensive Patients.
- The Relationship Between HHcy and Contrast-induced Nephropathy in Hypertensive Patients After Coronary Artery Diagnosis and Treatment (PHASE2, PHASE3)
- H-Type Hypertension Precision Medicine Trial (PHASE4)
- Feasibility Study of the Intensive Systolic Blood Pressure Control (PHASE4)
- CSPPT- Chronic Kidney Diseases Study (PHASE4)
- China Stroke Primary Prevention Trial (PHASE4)
- Effect of Enalapril Plus Folic Acid on Blood Pressure and Glycometabolism (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Enalapril/folic acid CI brief — competitive landscape report
- Enalapril/folic acid updates RSS · CI watch RSS
- Shenzhen Ausa Pharmed Co.,Ltd portfolio CI